Clinical trials: Ticagrelor
Acute Ischaemic Stroke, Transient Ischaemic Attack
[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]
The primary objective of the study is to compare the effect of 90-day treatment with ticagrelor (180 mg [two 90 mg tablets] loading dose on Day 1 followed by 90 mg twice daily maintenance dose for the remainder of the study) vs…
- Trial name
- SOCRATES (NCT01994720)
- Testing
- ticagrelor, Acetylsalicylic acid (ASA)
- Where
- 521 sites in United States, Argentina and 31 more
- Volunteers
- 13,307 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome
This study proposes to conduct the switch from ticagrelor to prasugrel in an organized stepwise manner, to allow for the evaluation of the relative efficacy of prasugrel versus ticagrelor using a stepped-wedge cluster randomized…
- Trial name
- SWITCH (NCT05183178)
- Testing
- Prasugrel 10 mg p.o, Ticagrelor 90 mg
- Where
- Sweden
- Volunteers
- 17,095 people
- Sponsor
- Vastra Gotaland Region
Stable Coronary Artery Disease
An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease
The purpose of the study is to determine the drug characteristics of Ticagrelor, and to determine if 4 weeks treatment will reduce the blood clotting.
- Trial name
- NCT01118325
- Testing
- ticagrelor, clopidogrel
- Where
- 13 sites in Japan, Philippines
- Volunteers
- 146 people
- Sponsor
- AstraZeneca
ST Elevation Myocardial Infarction, Fibrinolysis
Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial Infarction Post Fibrinolysis
This is a two-center, prospective, randomized, single-blind, investigator initiated, pharmacodynamic study of parallel design, carried out in 2 PCI-capable cardiology centers (Patras University Hospital and Konstantopoulio…
- Conditions
- ST Elevation Myocardial Infarction, Fibrinolysis, P2Y12 Inhibitor
- Trial name
- NCT01950416
- Testing
- Ticagrelor 180mg loading dose and 90mg bid maintenance dose, Clopidogrel 600mg loading dose and 150mg maintenance dose
- Where
- 2 sites in Greece
- Volunteers
- 56 people
- Sponsor
- University of Patras
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Change of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome
Acute coronary syndrome (ACS) guidelines have been changed, favoring dual antiplatelet therapy (DAPT) with the more potent P2Y12 inhibitor ticagrelor over clopidogrel (besides aspirin).
- Conditions
- Acute Coronary Syndrome, Percutaneous Coronary Intervention, Drug-Eluting Stents
- Trial name
- CHANGE DAPT (NCT03197298)
- Testing
- Clopidogrel, Ticagrelor
- Where
- Netherlands
- Volunteers
- 2,062 people
- Sponsor
- Thorax Centrum Twente
Acute Coronary Syndromes, Non ST Elevation Myocardial Infarction
Sub Lingual Versus Traditional Oral Administration of Ticagrelor in Acute Coronary Syndrome/Non ST-elevation Myocardial Infarction - A Platelet Reactivity Study
Our goal is to examine sub lingual versus traditional oral administration of ticagrelor in ACS/non ST-elevation Myocardial Infarction (NSTEMI) patients on platelet reactivity.
- Trial name
- NCT02402400
- Testing
- Sub Lingual Ticagrelor
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Sheba Medical Center
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)
The purpose of the study is to assess the efficacy (prevention of vascular events) and safety (especially bleedings) of Ticagrelor (AZD6140) compared with Clopidogrel, both given on top of low dose aspirin, in Asian/Japanese…
- Trial name
- NCT01294462
- Testing
- Ticagrelor, Clopidogrel, Acetylsalicylic acid ASA
- Where
- 87 sites in Japan, South Korea and 1 more
- Volunteers
- 801 people
- Sponsor
- AstraZeneca
Myocardial Infarction, Diabetes Mellitus
A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction
Taken together the results from CHARISMA and PEGASUS-TIMI54, it appears that physicians may consider extending beyond 1 year or reinitiating treatment with clopidogrel 75 mg od or ticagrelor 60mg bid in patients with a prior MI…
- Conditions
- Myocardial Infarction, Diabetes Mellitus, Renal Disease, Coronary Artery Disease
- Trial name
- ALTIC (NCT02663713)
- Testing
- Ticagrelor, Clopidogrel
- Where
- Greece
- Volunteers
- 20 people
- Sponsor
- University of Patras
Peripheral Arterial Disease
Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia
This is a single center, prospective, randomized, unblinded, open-label, active controlled pilot study to evaluate the efficacy and safety of ticagrelor plus aspirin versus clopidogrel plus aspirin in patients with Rutherford…
- Trial name
- NCT02230527
- Testing
- Ticagrelor, Clopidogrel
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- The Cleveland Clinic
Sickle Cell Disease
A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease
The purpose of this study is to determine whether ticagrelor is effective in reducing the number of days of pain, intensity of pain, and reducing the use of analgesics due to sickle cell disease
- Trial name
- Hestia2 (NCT02482298)
- Testing
- Ticagrelor
- Where
- 20 sites in United States, Egypt and 6 more
- Volunteers
- 87 people
- Sponsor
- AstraZeneca
Coronary Artery Disease
Impact of Renal Function on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients
Dual antiplatelet therapy consisting in aspirin and clopidogrel is the cornerstone of the treatment of the prevention of the thrombotic events in patients with coronary artery disease (CAD), showing a reduction in adverse events.
- Trial name
- Ticagrelor (NCT02323971)
- Testing
- Ticagrelor
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Stable Coronary Artery Disease
A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders
The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of…
- Trial name
- RESPOND (NCT00642811)
- Testing
- Ticagrelor, Clopidogrel, Aspirin
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Platelet Reactivity
Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis
Clopidogrel administration is commonly prescribed in patients undergoing percutaneous coronary intervention, in patients with previous stroke and in patients under chronic hemodialysis via fistulae.
- Trial name
- NCT01511471
- Testing
- Ticagrelor
- Where
- 2 sites in Greece
- Volunteers
- 20 people
- Sponsor
- University of Patras
Platelet Aggregation Inhibitors, Dual Anti-Platelet Therapy
Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention
The study is an investigator-sponsored, retrospective cohort study designed to compare efficacy and safety of ticagrelor in elderly patients undergoing percutaneous coronary intervention.
- Conditions
- Platelet Aggregation Inhibitors, Dual Anti-Platelet Therapy, Aged, Percutaneous Coronary Intervention
- Trial name
- NCT04999293
- Testing
- Ticagrelor
- Where
- China
- Volunteers
- 1,505 people
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
Acute Coronary Syndrome (ACS)
Platelet Function in Patients With an Acute Coronary Syndrome
The aims of the study are to: explore whether platelet reactivity in patients treated wih novel platelet inhibitors is associated with clinical outcome investigate whether a therapeutic window exist for novel platelet inhibitors…
- Trial name
- ATLANTIS-ACS (NCT01992484)
- Where
- Austria
- Volunteers
- 1,000 people
- Sponsor
- Medical University of Vienna
Hemorrhage, Surgical, Blood Loss, Surgical
Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)
Prospective, multi-center, double-blind, randomized pivotal trial to evaluate the safety and effectiveness of the DrugSorb-Antithrombotic Removal (ATR) system for intraoperative removal of ticagrelor in patients undergoing urgent…
- Conditions
- Hemorrhage, Surgical, Blood Loss, Surgical, Blood Loss, Postoperative, Hemorrhage Postoperative
- Trial name
- STAR-T (NCT04976530)
- Testing
- DrugSorb-ATR system
- Where
- 29 sites in United States, Canada
- Volunteers
- 140 people
- Sponsor
- CytoSorbents, Inc
Atrial Fibrillations, Heart Valve Prostheses
What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.
The optimal antithrombotic therapy for patients with atrial fibrillation (AF) with a CHA2DS2-VASc score ≥1 with concomitant acute coronary syndrome (ACS) or revascularisation by percutaneous coronary intervention (PCI) with…
- Conditions
- Atrial Fibrillations, Heart Valve Prostheses, Acute Coronary Syndromes, Coronary Artery Diseases
- Trial name
- WOEST 2 (NCT02635230)
- Testing
- Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.
- Where
- 9 sites in Belgium, Netherlands
- Volunteers
- 2,200 people
- Sponsor
- R&D Cardiologie
Infarction, Myocardial Infarction
Which Platelet Function Test Best Reflects the In Vivo Plasma Concentrations of Ticagrelor and Its Active Metabolite?
Ticagrelor is a direct-acting, reversible platelet P2Y12 receptor inhibitor recommended by the recent European Society of Cardiology guidelines in patients with acute coronary syndromes (ACS) (class of recommendation I, level of…
- Conditions
- Infarction, Myocardial Infarction, Cardiovascular Diseases, Heart Diseases
- Trial name
- HARMONIC (NCT02690454)
- Where
- Poland
- Volunteers
- 45 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Acute Coronary Syndrome
Platelet Aggregation During the Shift From Clopidogrel to Ticagrelor
Antiplatelet therapy with ticagrelor is currently indicated for treatment of patients presenting with acute coronary syndrome. Such therapy is started with the administration of a loading dose in patients which are not yet under…
- Trial name
- SHIFT-OVER (NCT01795820)
- Testing
- loading with Ticagrelor, no loading with Ticagrelor
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University Magna Graecia
Treatment of Acute Coronary Syndrome (ACS).
REalWorld Insights on the INitiation and Treatment Duration of ticagrEloR & Other Oral Antiplatelets (OAP) in Patients With Acute Coronary Syndrome (ACS) in Be/Lux.
REWINDER is a multinational, multicentre, non-interventional, retrospective study of patients treated with an oral antiplatelet (ticagrelor, prasugrel or clopidogrel) while in hospital after an acute coronary syndrome (ACS)…
- Trial name
- REWINDER (NCT02190123)
- Testing
- ACS patients treated with OAP
- Where
- 15 sites in Belgium
- Volunteers
- 430 people
- Sponsor
- AstraZeneca